Clinical Trial

Clinical Study on Lymphaticovenous Anastomosis(LVA) for the Treatment of Alzheimer's Disease(AD)

Study acronym: LVA; AD
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to explore the safety and efficacy of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD). The main questions it aims to answer are: 1. After LVA surgery treatment, do patients with AD show improvement in dementia, cognitive impairment, neurobehavioral symptoms? 2. What are the complications associated with LVA treatment for AD, including perioperative complications and long-term complications? 3. What is the mechanism of LVA treatment for AD patients, and what changes occur in AD-related biomarkers (Aβ42、 Aβ40、Aβ42/40、pTau217、pTau181) before and after surgery?
Trial Details
NCT Number NCT06918145
Lead Sponsor Peking University Third Hospital
Conditions Alzheimer's Disease (AD)
Enrollment 80 participants
Start Date 2025-04-02
Primary Completion 2030-03-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-09